LianMedical (LIANY)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was formerly known as LianBio and changed its name to LianMedical in July 2026. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Peers in Healthcare
LianMedical has no peer companies in this window.
Recent press releases
LianMedical has not issued a press release in this window.
SEC filings
All filings →LianMedical has not filed an SEC document in this window.
Insider trades
All insider trades →LianMedical has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at LianMedical
All people →No officers or directors have been indexed for LianMedical.
Quarterly financials
Full financials →No quarterly financials have been ingested for LianMedical.